Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 5:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sarcoidosis, Cardiac Clear all
Recruiting Phase 2 Interventional

Rilonacept in Subjects With Cardiac Sarcoidosis

NCT06660732
View directory record Official record
Conditions
Cardiac Sarcoidosis
Interventions
Rilonacept
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Jun 27, 2026, 5:24 AM EDT
Terminated Not applicable Interventional

Feasibility and Accuracy of Hybrid Magnetic Resonance and Positron Emission Tomography With 18F-Fluorodeoxyglucose in Diagnosing Cardiac Sarcoidosis

NCT03923049
View directory record Official record
Conditions
Cardiac Sarcoidosis
Interventions
hybrid PET/MRI
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Jun 27, 2026, 5:24 AM EDT
Completed Early Phase 1 Interventional

Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82

NCT03048097
View directory record Official record
Conditions
Sarcoidosis
Interventions
Fluorodeoxyglucose, Rubidium, FDG-PET/CT with Rb82 Myocardial Perfusion Imaging
Drug · Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 25, 2019 · Synced Jun 27, 2026, 5:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

UTSW HP [13-C] Pyruvate Injection in HCM

NCT03057002
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis, Becker Muscular Dystrophy, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Interventions
Hyperpolarized 13C-Pyruvate
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Jun 27, 2026, 5:24 AM EDT
Completed No phase listed Observational

Implantable Cardiac Defibrillators for the Prevention of Sudden Death in Patients With Cardiac Sarcoidosis

NCT01013311
View directory record Official record
Conditions
Sarcoidosis of the Heart, Cardiomyopathy
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Jun 27, 2026, 5:24 AM EDT
Recruiting Phase 2 Interventional

Repurposing Tilmanocept for Cardiac Sarcoidosis

NCT07159074
View directory record Official record
Conditions
Cardiac Sarcoidosis
Interventions
Tc 99m tilmanocept
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 27, 2026, 5:24 AM EDT
Not yet recruiting No phase listed Observational

Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS)

NCT07604220
View directory record Official record
Conditions
Cardiac Sarcoidosis, Sarcoidosis of the Heart, Sarcoidosis With Myocarditis, Sarcoidosis, Cardiac
Interventions
Exosome Analysis
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 27, 2026, 5:24 AM EDT
Completed Phase 2 Interventional

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

NCT03814317
View directory record Official record
Conditions
Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Inhaled Treprostinil
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jun 27, 2026, 5:24 AM EDT
Recruiting No phase listed Observational

Cardiovascular Multimodality Imaging Study

NCT06610019
View directory record Official record
Conditions
Non-ischemic Cardiomyopathy, Cardiomyopathies, Hypertrophic Cardiomyopathy, Right Ventricular Arrhythmogenic Cardiomyopathy, Cardiac Amyloidosis, Anderson Fabry Disease, Sarcoidosis, Cancer Therapy-related Cardiac Dysfunction, Ventricular Arrythmia, Heart Failure
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Jun 27, 2026, 5:24 AM EDT
Completed No phase listed Observational

Evaluation of MyoStrain™ in Clinical Practice

NCT03825224
View directory record Official record
Conditions
Cardiac Failure, Coronary Artery Disease, Sarcoidosis, Amyloidosis, Lupus, Myocarditis, Drug Toxicity
Interventions
Diagnostic Test: Myostrain
Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
Not listed
Enrollment
19 participants
Timeline
2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Jun 27, 2026, 5:24 AM EDT
Not yet recruiting Phase 2 Interventional

A Trial of Baricitinib in Patients With Cardiac Sarcoidosis

NCT06868381
View directory record Official record
Conditions
Cardiac Sarcoidosis
Interventions
Baricitinib (LY3009104) 4 mg
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jun 27, 2026, 5:24 AM EDT
Recruiting No phase listed Observational

Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis

NCT01745237
View directory record Official record
Conditions
Sarcoidosis
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
27,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2032
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Jun 27, 2026, 5:24 AM EDT
Completed Phase 4 Interventional Results available

d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis

NCT03549598
View directory record Official record
Conditions
Cardiac Sarcoidosis
Interventions
68Ga-DOTATATE PET/CT, 18FDG PET/CT scan, 13NH3 PET/CT scan
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Jun 27, 2026, 5:24 AM EDT
Completed No phase listed Observational

Routine Cardiac Screening in Sarcoidosis Patients

NCT03902223
View directory record Official record
Conditions
Sarcoidosis, Cardiac Sarcoidosis, Boeck's Disease, Besnier-Boeck Disease
Interventions
Enhanced Screening Protocol for Cardiac Sarcoidosis., Routine Screening for Suspected Cardiac Sarcoidosis
Diagnostic Test
Lead sponsor
Foundation for Sarcoidosis Research
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
10
States / cities
Denver, Colorado • Chicago, Illinois • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Jun 27, 2026, 5:24 AM EDT
Completed Not applicable Interventional Results available

Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis

NCT02546388
View directory record Official record
Conditions
Sarcoidosis
Interventions
Indium-111 Pentreotide, Gallium-68 DOTATATE
Drug
Lead sponsor
Marcelo F. Di Carli, MD, FACC
Other
Eligibility
18 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Jun 27, 2026, 5:24 AM EDT
Completed No phase listed Observational

PET Imaging in Patients With Suspected Cardiac Sarcoidosis

NCT03746847
View directory record Official record
Conditions
Cardiac Sarcoidosis
Interventions
Gallium-68 DOTATATE
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Jun 27, 2026, 5:24 AM EDT
Completed Not applicable Interventional Results available

Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability

NCT01615484
View directory record Official record
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions
Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™, STEEN Solution™
Procedure · Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Jun 27, 2026, 5:24 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cell Free DNA in Cardiac Sarcoidosis

NCT03858777
View directory record Official record
Conditions
Sarcoidosis With Myocarditis, Sarcoidosis, Healthy, ST Elevation Myocardial Infarction
Interventions
cell free DNA
Diagnostic Test
Lead sponsor
Nabeel Hamzeh
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jun 27, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis

NCT04017936
View directory record Official record
Conditions
Cardiac Sarcoidosis
Interventions
Anakinra
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Ann Arbor, Michigan • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jun 27, 2026, 5:24 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Mayo AVC Registry and Biobank

NCT03049254
View directory record Official record
Conditions
Arrhythmogenic Right Ventricular Cardiomyopathy, Cardiomyopathies, Heart Diseases, Cardiovascular Diseases, Sudden Cardiac Arrest, Sudden Cardiac Death, Arrhythmogenic Right Ventricular Dysplasia, Arrhythmogenic Ventricular Cardiomyopathy, Familial Dilated Cardiomyopathy, Cardiovascular Abnormalities, Sarcoidosis, Cardiac Arrhythmia, Cardiac Sarcoidosis, Myocarditis, Inflammatory Cardiomyopathy, Ventricular Tachycardia, Right Ventricular Outflow Tract Ventricular Tachycardia
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jun 27, 2026, 5:24 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis

NCT05351554
View directory record Official record
Conditions
Sarcoidosis, Cardiac
Interventions
Namilumab
Drug
Lead sponsor
Kinevant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
12
States / cities
Palo Alto, California • Denver, Colorado • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Jun 27, 2026, 5:24 AM EDT
Recruiting Phase 3 Interventional

Cardiac Sarcoidosis Randomized Trial

NCT03593759
View directory record Official record
Conditions
Cardiac Sarcoidosis, Sarcoidosis
Interventions
Prednisone or Prednisolone, Methotrexate
Drug
Lead sponsor
Ottawa Heart Institute Research Corporation
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
New Haven, Connecticut • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 27, 2026, 5:24 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression

NCT06510894
View directory record Official record
Conditions
Cardiac Sarcoidosis
Interventions
Sotagliflozin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jun 27, 2026, 5:24 AM EDT
Terminated Phase 2 Interventional Results available

18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation

NCT03103490
View directory record Official record
Conditions
Cardiac Sarcoidosis, Myocardial Inflammation
Interventions
18F-FSPG
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Jun 27, 2026, 5:24 AM EDT